← All trials
NCT06076291
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2023
- Primary completion
- Dec 28, 2024
- Completion date
- Mar 28, 2025
- First posted
- Oct 10, 2023
- Last posted
- Nov 21, 2023
- Enrollment
- 122
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hangzhou Sumgen Biotech Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.